IL-23 drives Th17 differentiation and sustains inflammatory responses, making it a critical target in autoimmune and tumor immunology research. This recombinant human IL-23 heterodimer (IL-23A aa 20–189 paired with IL-12B aa 23–328) demonstrates confirmed signaling potency with an ED50 of 70–210 ng/mL in a STAT reporter assay using 293F cells, supporting JAK/STAT pathway studies, Th17 polarization assays, and functional screening in antibody development campaigns. The C-terminal 6×His tag enables straightforward purification and oriented immobilization for use as a coating antigen in ELISA or as a reference standard in cytokine detection platforms. Mammalian-expressed to preserve native folding and post-translational modifications, this heterodimer provides greater than 95% purity and endotoxin levels below 1.0 EU/μg, satisfying the stringent criteria required to prevent LPS-driven artifacts in primary immune cell activation and in vivo inflammation models.
Email: support@cusabio.com
Distributors Worldwide